A Single Daily Dose of a New Form of Amitriptyline in Depressive Illness

1972 ◽  
Vol 120 (558) ◽  
pp. 521-522 ◽  
Author(s):  
Ijaz Haider
Keyword(s):  
Sustained Release ◽  
Clinical Experience ◽  
Depressive Illness ◽  
Single Daily Dose ◽  
Once Daily ◽  
Sustained Release Form ◽  
Daily Dose ◽  
The Common ◽  
New Form ◽  
Release Form

In order to try to overcome the common clinical experience of patients who do not take the drugs prescribed for them (Wilcox et al., 1965) a sustained release form of amitriptyline (Lentizol) has recently been made available. This trial was undertaken to test the efficacy of this formulation given once daily at night compared to standard amitriptyline given thrice daily.

Trial of a Sustained Release Form of Amitriptyline (Lentizol) in the Treatment of Depressive Illness

1973 ◽  
Vol 123 (572) ◽  
pp. 69-71 ◽  
Author(s):  
G. Sedman
Keyword(s):  
Single Dose ◽  
Sustained Release ◽  
Dosage Level ◽  
Depressive Illness ◽  
Double Blind ◽  
Sustained Release Form ◽  
Release Form

The advantages of a new sustained release form of amitriptyline (Lentizol) which can be given in a single dose for the treatment of depressive illness have recently been described by Sims (1972) and Haider (1972). This paper reports a similar double blind cross-over trial in the treatment of depressive illness (ICD 296) of the same substance compared against conventional amitriptyline at an overall higher dosage level.

Trial of a Sustained Release Form of Amitriptyline in the Treatment of Depressive Illness

1972 ◽  
Vol 120 (554) ◽  
pp. 65-67 ◽  
Author(s):  
A. C. P. Sims
Keyword(s):  
Failure Rate ◽  
Tricyclic Antidepressants ◽  
Psychiatric Patients ◽  
Depressive Illness ◽  
Single Daily Dose ◽  
High Failure Rate ◽  
Double Blind ◽  
Daily Dose ◽  
Release Form ◽  
Patient Studies

Amitriptyline is a widely used antidepressant and its effectiveness has been shown, e.g. in comparison with imipramine in double blind trial (Burt et al., 1962; Hordern et al., 1963, 1964). A disadvantage of currently prescribed tricyclic antidepressants is the necessity for administering the drug three times a day. It has been shown that general medical and in particular psychiatric patients fail to take their medication either in the prescribed dose or at all (Benstead and Theobald, 1952; Haler, 1952; Park and Lipman, 1964; Parkes et al., 1962; Porter, 1969). This failure rate may be as high as 50 per cent (Dixon et al., 1957; Willcox et al., 1965). Even in psychiatric in-patient studies there was still a high failure rate in taking prescribed psychiatric drugs (Hare and Willcox, 1967). A regimen consisting of a single daily dose is more reliably taken than one consisting of thrice daily dosage (Coppen et al., 1969; General Practitioner Clinical Trial 1970).

A Single Daily Dose of a New Form of Amitriptyline in Depressive Illness

1972 ◽  
Vol 121 (563) ◽  
pp. 457-457 ◽  
Author(s):  
Arthur Rifkin ◽  
Frederic Quitkin ◽  
Donald F. Klein
Keyword(s):  
Depressive Illness ◽  
Single Daily Dose ◽  
Daily Dose ◽  
New Form

Treatment of hyperthyroidism with a small single daily dose of methimazole

1988 ◽  
Vol 119 (1) ◽  
pp. 139-144 ◽  
Author(s):  
Yasuo Mashio ◽  
Mutsuo Beniko ◽  
Akemi Ikota ◽  
Hiroaki Mizumoto ◽  
Haruhiko Kunita
Keyword(s):  
Divided Dose ◽  
Dose Regimen ◽  
Single Daily Dose ◽  
Once Daily ◽  
Daily Dose ◽  
The Mean ◽  
Time Required ◽  
Daily Dose Regimen ◽  
Mean Time ◽  
Immunoglobulin Levels

Abstract. A prospective randomized trial with the conventional divided doses (10 mg 3 times daily, N = 29) and a small single daily dose (15 mg once daily, N = 25) of methimazole for the treatment of Graves' hyperthyroidism was performed. Within 8 weeks, almost 80% of the patients in both groups became euthyroid. The mean time required to achieve the euthyroid state was 6.0 ± 2.8 and 6.0 ± 3.8 weeks, respectively. TSH binding inhibitor immunoglobulin was found in about 90% of the patients in both groups before methimazole treatment. However, a gradual fall of its levels was observed in nearly all patients after treatment. There was no difference in the mean levels of TSH binding inhibitor immunoglobulin between the two groups during therapy. We conclude that the single daily dose regimen of 15 mg of methimazole will control Graves' hyperthyroidism in most patients, and TSH binding inhibitor immunoglobulin levels decrease in this regimen in the same way as with the conventional divided dose regimen (10 mg 3 times daily).

Human Availability Studies of Five Vitamins in Sustained Release Form

1961 ◽  
Vol 9 (3) ◽  
pp. 324-330 ◽  
Author(s):  
SAMUEL M. GREENBERG ◽  
JOHN F. HERNDON ◽  
DONALD R. MACDONNELL ◽  
THOMAS L. FLANAGAN ◽  
AMADEO BONDI
Keyword(s):  
Sustained Release ◽  
Sustained Release Form ◽  
Release Form

Amitriptyline Dosage Schedule, Sampling Time and Tricyclic Plasma Levels

1977 ◽  
Vol 131 (2) ◽  
pp. 168-171 ◽  
Author(s):  
Vincent E. Ziegler ◽  
David A. Meyer ◽  
Samuel H. Rosen ◽  
John W. Knesevich ◽  
John T. Biggs
Keyword(s):  
Sustained Release ◽  
Plasma Levels ◽  
Half Life ◽  
Single Daily Dose ◽  
Sampling Time ◽  
Dosage Schedule ◽  
Morning Dose ◽  
Daily Schedule ◽  
Daily Dose ◽  
Amitriptyline Hydrochloride

SummaryPlasma levels of amitriptyline and nortriptyline were similar in ten depressed patients after administration of amitriptyline hydrochloride in three divided doses or as a single daily dose. Maximum comparability of the plasma levels is achieved by sampling 12 to 16 hours after the single daily dose, or 3 to 7 hours after the morning dose on a thrice-daily schedule. Owing to the long biological half-life of these drugs, therapeutic plasma levels are maintained on a once a day dosage schedule, and the need for sustained release preparations appears questionable.

Once-Daily Dosing with Phenobarbital in Children with Seizure Disorders

PEDIATRICS ◽  
1981 ◽  
Vol 68 (6) ◽  
pp. 824-827
Author(s):  
Anne G. Davis ◽  
Kelly D. Mutchie ◽  
Joel A. Thompson ◽  
Garth G. Myers
Keyword(s):  
Adverse Reactions ◽  
Pediatric Patients ◽  
Seizure Activity ◽  
Single Daily Dose ◽  
Daily Regimen ◽  
Serum Concentrations ◽  
Once Daily ◽  
Seizure Disorders ◽  
Daily Dose

In nine pediatric patients with seizure disorders, aged 8 months to 16½ years, a single daily dose of phenobarbital was as effective in maintaining therapeutic serum concentrations as twice-daily dosing. There were no adverse reactions to the once-daily regimen, and no seizure activity occurred during the study as a result of the change in dosing pattern.

scholarly journals Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder

2012 ◽  
Vol 69 (2) ◽  
pp. 201-204 ◽  
Author(s):  
Aneta Lakic
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Depressive Symptoms ◽  
Side Effects ◽  
Sustained Release ◽  
Attention Deficit ◽  
Depressive Symptomatology ◽  
Hyperactivity Disorder ◽  
Sustained Release Form ◽  
The Brain ◽  
Release Form

Introduction. Hyperkinetic disorder or attention-deficit hyperactivity disorder (ADHD) is a clinical entity consisting of a cluster of symptoms including hyperactivity, attention disorder and impulse control disorder group. In the context of ADHD etiology we may say that genetic, clinical and imaging studies point out a disruption of the brain dopamine system, which is corroborated by the clinical effectiveness of stimulant drugs, which increase extracellular dopamine in the brain. Basically, it is a biological and not psychological disorder, which is important both for the comprehension and therapeutical approach to this problem. Today, the best recommended approach regarding children with ADHD is a combination of two therapeutic modalities: pharmacotherapy and behavioral treatment. The first-choice drugs for this disorder belong to the group of sympathomimetics - psychostimulants and atomoxetine (more recently). As the firstchoice therapy, methylphenydate in sustained release form has numerous advantages. Like all drugs, methylphenidate has its unwanted side effects. Most common are: loss of appetite, weight loss, sleeping disorders, irritability, headache. These side effects are well-known and documented in the literature. By analysing the available literature we have found cases of psychiatric side effects such as: psychosis, mania, visual hallucinations, agitation, suicidal ideas. We have not found examples of ADHD in children who use increased dosage of sustained release of methylphenidate leading to depressive symptomatology. On the other side, methylphenidate may be prescribed for off-label use in treatmentresistant cases of depression. Case report. The case of a 7- year-old boy diagnosed with ADHD was on a minimal dose of sustained release form of methylphenidate. After initial titration of the drug, i.e. after raising the dose to the next level the boy developed clinical signs of depression. The treatment was ceased and depressive symptoms were withdrawed. Conclusion. Manifestation of depressive symptomatology after dose increasement of sustained release form of methylphenidate in a 7-year-old boy with ADHD represents an uncommon side effect. Precise drug activity mechanisms responsible for the appearance of these symptoms remains to be explained.

Sign in / Sign up

Export Citation Format

Share Document